Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Long intergenic non-protein coding RNA 426 (LINC00426)
- Target
- LINC00426
- Molecular classification
- Long non-coding RNA (lncRNA), Other (Non-protein coding RNA family)
01
Overview
Long intergenic non-protein coding RNA 426 (LINC00426) is a long non-coding RNA (lncRNA) gene found in the human genome at locus 13q12.3 on the DNA antisense strand. It spans 38,105 bases and does not encode a protein. LINC00426 has been shown to be ectopically expressed in a variety of human cancers, including lung adenocarcinoma and breast cancer. In lung adenocarcinoma, it promotes tumor cell proliferation, migration, invasion, and metastasis, operating as a ceRNA that sponges miR-455-5p and modulates UBE2V1 expression, influencing pathways associated with cytoskeleton rearrangement and EMT. In breast cancer, its expression correlates with immune cell infiltration and prognostic outcomes, serving as an immune phenotype marker. It is being investigated as a potential biomarker for diagnostics and prognostics in several tumor types but is not yet a classic therapeutic target. There are currently no approved drugs directly modulating LINC00426, and therapeutic approaches targeting it would face RNA delivery and specificity challenges.
- Other names
- LINC00426long intergenic non-protein coding RNA 426
02
Mechanism of action
Null LINC00426 is not itself a drug target. Its function relates to regulatory effect on other genes/microRNAs (e.g., via sponging miR-455-5p)
03
Biological functions
Regulation of gene expression (via acting as a competing endogenous RNA, or ceRNA, to sponge microRNAs such as miR-455-5p)Promotion of cell proliferation, invasion, and metastasis, particularly in lung adenocarcinoma (LUAD)Modulation of epithelial–mesenchymal transition (EMT) in cancer cellsRegulation of cytoskeleton rearrangement and matrix metalloproteinase (MMP) expressionImmune phenotype modulation and correlation with immune-cell infiltration in some cancers, e.g., breast cancer
04
Disease associations
CancerLung adenocarcinoma (onco-promoting role)Breast cancer (prognostic marker, immune microenvironment correlation)Osteosarcoma (doxorubicin resistance)Clear cell renal cell carcinoma (immune infiltration correlation)Hepatocellular carcinoma (prognostic)
05
Safety considerations
Lack of direct targeting strategies, since LINC00426 is an RNA and not a proteinPotential off-target effects or delivery challenges if using antisense oligonucleotides/RNA therapeutic approaches
06
Interacting drugs
None
07
Biomarkers
LINC00426 tissue or blood expression levels (as a diagnostic/prognostic biomarker in lung cancer, breast cancer, hepatocellular carcinoma, etc.)Linked to prognosis and immune phenotype in breast cancer
Beyond the preview
Go deeper on Long intergenic non-protein coding RNA 426 (LINC00426).
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow the clinical studies evaluating therapies directed at this target.
- Trial design
- Status
- Readouts
Competitive landscape
Full profile accessCompare approaches across drug candidates, modalities, and indications.
- Programs
- Modalities
- Indications
Literature & evidence
Full profile accessInvestigate the research and source evidence behind target biology and development.
- Publications
- Sources
- Analysis
Patents
Full profile accessExplore patent activity around therapies and technologies addressing this target.
- Patents
- Assignees
- Technologies
Research & analysis
Full profile accessConnect target biology, drug development, and emerging evidence in your research.
- Biology
- Development news
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Long intergenic non-protein coding RNA 426 (LINC00426).